 David Higgins
Concepts (194)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis B | 3 | 2023 | 70 | 2.360 |
Why?
| | Pregnancy Complications, Infectious | 2 | 2023 | 394 | 1.210 |
Why?
| | Rural Health Services | 1 | 2024 | 128 | 0.820 |
Why?
| | Hepatitis B Vaccines | 1 | 2023 | 45 | 0.810 |
Why?
| | Gonorrhea | 1 | 2023 | 59 | 0.770 |
Why?
| | Chlamydia Infections | 1 | 2023 | 75 | 0.770 |
Why?
| | Sexual Health | 1 | 2023 | 59 | 0.770 |
Why?
| | Physicians, Primary Care | 1 | 2024 | 236 | 0.720 |
Why?
| | Sexually Transmitted Diseases | 1 | 2023 | 161 | 0.710 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2023 | 213 | 0.700 |
Why?
| | Ventricular Function, Left | 3 | 2024 | 534 | 0.640 |
Why?
| | Sexual and Gender Minorities | 1 | 2023 | 214 | 0.630 |
Why?
| | Mitral Valve Insufficiency | 3 | 2024 | 68 | 0.620 |
Why?
| | HIV Infections | 2 | 2023 | 2836 | 0.590 |
Why?
| | Vaccination | 5 | 2024 | 1381 | 0.580 |
Why?
| | Vaccines | 1 | 2023 | 406 | 0.580 |
Why?
| | Anti-HIV Agents | 1 | 2023 | 778 | 0.520 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2017 | 58 | 0.520 |
Why?
| | Attitude of Health Personnel | 1 | 2024 | 1171 | 0.510 |
Why?
| | Practice Patterns, Physicians' | 1 | 2024 | 1313 | 0.480 |
Why?
| | Mycobacterium tuberculosis | 5 | 2010 | 314 | 0.470 |
Why?
| | Telemedicine | 1 | 2023 | 862 | 0.440 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2017 | 385 | 0.430 |
Why?
| | Tuberculosis, Pulmonary | 3 | 2010 | 141 | 0.430 |
Why?
| | Hepatitis B Surface Antigens | 2 | 2023 | 24 | 0.420 |
Why?
| | Heart Ventricles | 1 | 2017 | 788 | 0.380 |
Why?
| | Interleukin-10 | 3 | 2014 | 302 | 0.360 |
Why?
| | Vitamin D Deficiency | 1 | 2012 | 186 | 0.330 |
Why?
| | Stroke Volume | 3 | 2024 | 612 | 0.320 |
Why?
| | Cross Infection | 1 | 2012 | 256 | 0.310 |
Why?
| | Mitral Valve | 3 | 2024 | 88 | 0.310 |
Why?
| | Implants, Experimental | 1 | 2009 | 21 | 0.310 |
Why?
| | Foreign-Body Reaction | 1 | 2009 | 31 | 0.310 |
Why?
| | Tuberculosis | 3 | 2010 | 279 | 0.300 |
Why?
| | Vitamin D | 1 | 2012 | 397 | 0.290 |
Why?
| | Macrophage Colony-Stimulating Factor | 1 | 2008 | 21 | 0.290 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2008 | 152 | 0.270 |
Why?
| | Intensive Care Units | 1 | 2012 | 827 | 0.250 |
Why?
| | Length of Stay | 1 | 2012 | 1215 | 0.250 |
Why?
| | Pregnancy | 3 | 2023 | 6763 | 0.250 |
Why?
| | Female | 16 | 2024 | 73304 | 0.250 |
Why?
| | Critical Illness | 1 | 2012 | 811 | 0.250 |
Why?
| | Magnetic Resonance Imaging, Cine | 2 | 2024 | 193 | 0.240 |
Why?
| | Humans | 20 | 2024 | 137585 | 0.240 |
Why?
| | Biocompatible Materials | 1 | 2009 | 425 | 0.230 |
Why?
| | Mass Screening | 2 | 2023 | 1287 | 0.230 |
Why?
| | Pandemics | 2 | 2023 | 1639 | 0.230 |
Why?
| | Ventricular Function, Right | 2 | 2024 | 285 | 0.230 |
Why?
| | Heart Failure | 1 | 2017 | 2236 | 0.210 |
Why?
| | Blood Coagulation Tests | 1 | 2023 | 67 | 0.210 |
Why?
| | Hepatitis B virus | 1 | 2023 | 40 | 0.200 |
Why?
| | Sepsis | 2 | 2022 | 617 | 0.190 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 2 | 2014 | 52 | 0.190 |
Why?
| | HIV | 1 | 2023 | 234 | 0.190 |
Why?
| | Homosexuality, Male | 1 | 2023 | 184 | 0.190 |
Why?
| | Predictive Value of Tests | 2 | 2024 | 2031 | 0.180 |
Why?
| | Ventricular Remodeling | 1 | 2024 | 266 | 0.180 |
Why?
| | Infant, Newborn | 2 | 2023 | 6079 | 0.180 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2023 | 184 | 0.180 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2022 | 148 | 0.180 |
Why?
| | Exercise Test | 1 | 2024 | 625 | 0.180 |
Why?
| | Child | 6 | 2024 | 21935 | 0.170 |
Why?
| | Retrospective Studies | 4 | 2023 | 15657 | 0.170 |
Why?
| | Disease Progression | 3 | 2017 | 2757 | 0.160 |
Why?
| | Feasibility Studies | 1 | 2024 | 956 | 0.160 |
Why?
| | Macrophages | 1 | 2008 | 1547 | 0.160 |
Why?
| | Pneumonia, Aspiration | 2 | 2013 | 18 | 0.160 |
Why?
| | Infant | 2 | 2024 | 9465 | 0.160 |
Why?
| | Influenza Vaccines | 1 | 2024 | 539 | 0.160 |
Why?
| | Echocardiography | 2 | 2024 | 642 | 0.150 |
Why?
| | Chemokines, C | 2 | 2008 | 5 | 0.150 |
Why?
| | Genomics | 1 | 2023 | 795 | 0.140 |
Why?
| | Hospitals | 1 | 2023 | 691 | 0.140 |
Why?
| | Deglutition Disorders | 2 | 2013 | 143 | 0.140 |
Why?
| | Ferritins | 1 | 2017 | 64 | 0.140 |
Why?
| | RNA, Small Interfering | 2 | 2010 | 622 | 0.140 |
Why?
| | Male | 10 | 2024 | 67762 | 0.130 |
Why?
| | Antiviral Agents | 1 | 2023 | 744 | 0.130 |
Why?
| | United States | 2 | 2024 | 14841 | 0.130 |
Why?
| | Adult | 6 | 2024 | 37929 | 0.120 |
Why?
| | Transforming Growth Factor beta | 2 | 2009 | 480 | 0.120 |
Why?
| | Lung | 5 | 2013 | 4060 | 0.120 |
Why?
| | Tracheostomy | 1 | 1997 | 133 | 0.120 |
Why?
| | Iron | 1 | 2017 | 313 | 0.120 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2023 | 1329 | 0.120 |
Why?
| | Parents | 1 | 2023 | 1347 | 0.110 |
Why?
| | Colorado | 1 | 2024 | 4565 | 0.110 |
Why?
| | Th1 Cells | 3 | 2010 | 143 | 0.110 |
Why?
| | Cytokines | 4 | 2010 | 2085 | 0.110 |
Why?
| | Heme Oxygenase (Decyclizing) | 1 | 2013 | 22 | 0.110 |
Why?
| | Primary Health Care | 1 | 2024 | 1738 | 0.110 |
Why?
| | Propranolol | 1 | 2013 | 50 | 0.100 |
Why?
| | Mice | 9 | 2014 | 17787 | 0.100 |
Why?
| | Sialorrhea | 1 | 2013 | 1 | 0.100 |
Why?
| | Brain Neoplasms | 1 | 2022 | 1238 | 0.100 |
Why?
| | Interferon-gamma | 4 | 2010 | 789 | 0.100 |
Why?
| | Neuromuscular Agents | 1 | 2013 | 35 | 0.100 |
Why?
| | Metabolic Diseases | 1 | 2013 | 108 | 0.100 |
Why?
| | Botulinum Toxins, Type A | 1 | 2013 | 45 | 0.100 |
Why?
| | Biomarkers | 2 | 2017 | 4149 | 0.090 |
Why?
| | Middle Aged | 4 | 2024 | 33479 | 0.090 |
Why?
| | Critical Care | 1 | 1997 | 601 | 0.090 |
Why?
| | Surveys and Questionnaires | 1 | 2024 | 5778 | 0.090 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2008 | 1091 | 0.090 |
Why?
| | Confidence Intervals | 1 | 2012 | 329 | 0.090 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2013 | 323 | 0.090 |
Why?
| | Macrophages, Alveolar | 2 | 2014 | 391 | 0.090 |
Why?
| | Lymphocyte Activation | 3 | 2010 | 1142 | 0.090 |
Why?
| | Prospective Studies | 3 | 2024 | 7604 | 0.090 |
Why?
| | Quality of Life | 1 | 2022 | 2892 | 0.080 |
Why?
| | Follow-Up Studies | 2 | 2017 | 5131 | 0.080 |
Why?
| | Pulmonary Fibrosis | 1 | 2014 | 402 | 0.080 |
Why?
| | Patient Admission | 1 | 2012 | 197 | 0.080 |
Why?
| | Animals | 11 | 2014 | 36940 | 0.080 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2010 | 165 | 0.080 |
Why?
| | Cause of Death | 1 | 2012 | 434 | 0.080 |
Why?
| | Child, Preschool | 1 | 2024 | 11074 | 0.080 |
Why?
| | Hemorrhage | 1 | 2014 | 722 | 0.080 |
Why?
| | Bone Marrow Cells | 1 | 2010 | 316 | 0.080 |
Why?
| | Risk Factors | 1 | 2023 | 10388 | 0.080 |
Why?
| | Prognosis | 1 | 2017 | 4030 | 0.070 |
Why?
| | Lymphocyte Subsets | 1 | 2009 | 87 | 0.070 |
Why?
| | Proportional Hazards Models | 1 | 2012 | 1266 | 0.070 |
Why?
| | Oximetry | 1 | 2009 | 96 | 0.070 |
Why?
| | Neoplasms | 1 | 2023 | 2671 | 0.070 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2008 | 50 | 0.070 |
Why?
| | Immunohistochemistry | 2 | 2009 | 1738 | 0.070 |
Why?
| | Chronic Disease | 3 | 2010 | 1793 | 0.070 |
Why?
| | Flow Cytometry | 2 | 2009 | 1178 | 0.070 |
Why?
| | Cell Count | 1 | 2008 | 324 | 0.070 |
Why?
| | Monocytes | 1 | 2010 | 563 | 0.070 |
Why?
| | Granuloma | 1 | 2007 | 92 | 0.070 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2007 | 173 | 0.070 |
Why?
| | Immune Tolerance | 1 | 2009 | 363 | 0.060 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2008 | 367 | 0.060 |
Why?
| | Mice, Inbred C57BL | 4 | 2010 | 5757 | 0.060 |
Why?
| | Observer Variation | 2 | 2024 | 343 | 0.060 |
Why?
| | Reproducibility of Results | 2 | 2024 | 3284 | 0.060 |
Why?
| | Patient Discharge | 1 | 2012 | 897 | 0.060 |
Why?
| | Aged | 4 | 2024 | 23961 | 0.060 |
Why?
| | Mice, Knockout | 2 | 2010 | 3015 | 0.060 |
Why?
| | Prevalence | 1 | 2012 | 2734 | 0.060 |
Why?
| | Fibrosis | 2 | 2023 | 552 | 0.060 |
Why?
| | Adolescent | 1 | 2024 | 21513 | 0.060 |
Why?
| | Dendritic Cells | 1 | 2008 | 483 | 0.060 |
Why?
| | Pneumonia | 1 | 2010 | 639 | 0.050 |
Why?
| | Asymptomatic Diseases | 1 | 2024 | 89 | 0.050 |
Why?
| | Cells, Cultured | 2 | 2008 | 4193 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2008 | 1946 | 0.050 |
Why?
| | Lung Diseases, Interstitial | 1 | 2009 | 638 | 0.050 |
Why?
| | Cardiac Volume | 1 | 2001 | 13 | 0.050 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2007 | 900 | 0.040 |
Why?
| | Treatment Outcome | 2 | 2013 | 10811 | 0.040 |
Why?
| | Precision Medicine | 1 | 2023 | 429 | 0.040 |
Why?
| | Phenotype | 1 | 2008 | 3196 | 0.040 |
Why?
| | Transcriptome | 1 | 2022 | 971 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2022 | 1774 | 0.030 |
Why?
| | Monitoring, Physiologic | 1 | 1997 | 275 | 0.030 |
Why?
| | Hemosiderin | 1 | 2014 | 2 | 0.030 |
Why?
| | Bleeding Time | 1 | 2014 | 7 | 0.030 |
Why?
| | Fibrin | 1 | 2014 | 81 | 0.030 |
Why?
| | Enzyme Induction | 1 | 2013 | 90 | 0.030 |
Why?
| | Mice, Inbred Strains | 1 | 2014 | 409 | 0.030 |
Why?
| | Myofibroblasts | 1 | 2014 | 127 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 1997 | 1483 | 0.020 |
Why?
| | Movement Disorders | 1 | 2013 | 58 | 0.020 |
Why?
| | Intubation, Gastrointestinal | 1 | 2013 | 79 | 0.020 |
Why?
| | Injections | 1 | 2013 | 183 | 0.020 |
Why?
| | Patient Care Team | 1 | 1997 | 631 | 0.020 |
Why?
| | Ultrasonography, Interventional | 1 | 2013 | 141 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2024 | 3566 | 0.020 |
Why?
| | Disease Models, Animal | 2 | 2014 | 4295 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 786 | 0.020 |
Why?
| | Butylated Hydroxytoluene | 1 | 2010 | 38 | 0.020 |
Why?
| | Infrared Rays | 1 | 2009 | 25 | 0.020 |
Why?
| | Interleukin-4 | 1 | 2010 | 216 | 0.020 |
Why?
| | Cell Polarity | 1 | 2010 | 141 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2009 | 298 | 0.020 |
Why?
| | Survival Rate | 1 | 2013 | 1972 | 0.020 |
Why?
| | Patient Satisfaction | 1 | 2013 | 660 | 0.020 |
Why?
| | Early Diagnosis | 1 | 2009 | 242 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2008 | 332 | 0.020 |
Why?
| | Gene Silencing | 1 | 2008 | 195 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2013 | 2486 | 0.020 |
Why?
| | Aerosols | 1 | 2008 | 176 | 0.020 |
Why?
| | Administration, Inhalation | 1 | 2008 | 688 | 0.020 |
Why?
| | Sex Factors | 1 | 2013 | 2071 | 0.020 |
Why?
| | Rats | 1 | 2013 | 5647 | 0.010 |
Why?
| | Oxygen | 1 | 2009 | 931 | 0.010 |
Why?
| | Hospitalization | 1 | 2013 | 2199 | 0.010 |
Why?
| | Cohort Studies | 1 | 2013 | 5742 | 0.010 |
Why?
| | Phantoms, Imaging | 1 | 2001 | 152 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2008 | 1996 | 0.010 |
Why?
| | Swine | 1 | 2001 | 775 | 0.010 |
Why?
|
|
Higgins's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|